Curis, Inc. announced that Jaye Viner, M.D., the Chief Medical Officer and Executive Vice President, will depart the Company effective as of February 26, 2016. Michael P. Gray, the Chief Financial Officer and Chief Business Officer of the Company, has provided to the Company notice of his intention to resign from the Company, effective as of February 29, 2016. On January 19, 2016, the board of directors of the Company promoted David Tuck, M.D. to the position of Senior Vice President, Clinical and Translational Sciences, and to the role of executive officer of the Company.

On January 19, 2016, the Board also promoted Mani Mohindru, Ph.D., Senior Vice President of Corporate Strategy and Investor Relations, to the role of executive officer of the Company. Dr. Tuck previously served as the Company's Vice President of Clinical and Translational Sciences from May 2015 through January 2016. He joined the Company from EMD Serono where he was Senior Medical Director in the Oncology Translational Innovation Program from 2013 until May 2015, with activities ranging from early clinical development of small molecule and biologic targeted therapeutics, to novel target and biomarker identification focused on bioinformatics and genomics analysis.

Dr. Mohindru has served as the Company's Senior Vice President of Corporate Strategy and Investor Relations since April 2015.